Sona Nanotech Past Earnings Performance
Past criteria checks 0/6
Sona Nanotech has been growing earnings at an average annual rate of 16%, while the Life Sciences industry saw earnings growing at 11.7% annually.
Key information
16.0%
Earnings growth rate
23.0%
EPS growth rate
| Life Sciences Industry Growth | 26.8% |
| Revenue growth rate | n/a |
| Return on equity | n/a |
| Net Margin | n/a |
| Last Earnings Update | 31 Jul 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Sona Nanotech makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Jul 24 | 0 | -3 | 2 | 0 |
| 30 Apr 24 | 0 | -3 | 2 | 1 |
| 31 Jan 24 | 0 | -3 | 2 | 0 |
| 31 Oct 23 | 0 | -2 | 2 | 0 |
| 31 Jul 23 | 0 | -1 | 1 | 0 |
| 30 Apr 23 | 0 | -1 | 1 | 0 |
| 31 Jan 23 | 0 | -2 | 2 | 0 |
| 31 Oct 22 | 0 | -2 | 3 | 0 |
| 31 Jul 22 | 0 | -5 | 6 | 0 |
| 30 Apr 22 | 0 | -6 | 7 | 0 |
| 31 Jan 22 | 0 | -8 | 9 | 0 |
| 31 Oct 21 | 0 | -10 | 11 | 0 |
| 31 Jul 21 | 0 | -12 | 12 | 1 |
| 30 Apr 21 | 0 | -12 | 11 | 1 |
| 31 Jan 21 | 0 | -10 | 9 | 0 |
| 31 Oct 20 | 0 | -6 | 6 | 0 |
| 31 Jul 20 | 0 | -3 | 3 | 0 |
| 30 Apr 20 | 0 | -3 | 2 | 0 |
| 31 Jan 20 | 0 | -3 | 2 | 0 |
| 31 Oct 19 | 0 | -3 | 2 | 0 |
| 31 Jul 19 | 0 | -7 | 2 | 0 |
| 30 Apr 19 | 0 | -6 | 1 | 0 |
| 31 Jan 19 | 0 | -5 | 1 | 0 |
| 31 Oct 18 | 0 | -5 | 1 | 0 |
| 31 Jul 18 | 0 | -1 | 1 | 0 |
| 31 Oct 17 | 0 | 0 | 1 | 0 |
Quality Earnings: SONA is currently unprofitable.
Growing Profit Margin: SONA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: SONA is unprofitable, but has reduced losses over the past 5 years at a rate of 16% per year.
Accelerating Growth: Unable to compare SONA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SONA is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (-4.7%).
Return on Equity
High ROE: SONA's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.